Skip to main content

Phase 3 Readout

AZN: Phase 3 Topline: A Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate

November 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
November 30, 2026
Company
ASTRAZENECA PLC (AZN)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate

AZN overview →
Indication
Eosinophilic Granulomatous Vasculitis

Other upcoming events for AZN

Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoe
Phase 3 ReadoutPhase 3 Topline: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemothera
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combinati
Phase 3 ReadoutPhase 3 Topline: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line
Phase 3 ReadoutPhase 3 Topline: A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compa